Results 131 to 140 of about 34,211 (250)
A comprehensive review of cancer‐induced cardiac wasting
British Journal of Pharmacology, EarlyView.Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena +5 more
wiley +1 more source
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam +3 more
wiley +1 more source
Bioinformatic Analysis and Refactoring of Higher Anthracyclines
Anthracyclines, renowned for their potent antibiotic and antitumor properties, stand as symbolic aromatic polyketides with diverse therapeutic applications, particularly in cancer treatment.
Muthuwa Hannedige, Tharika Dilhari
core +1 more source
Quantitative liquid chromatographic analysis of anthracyclines in biological fluids
, 2009 The optimization, validation and application of a liquid chromatographic method with fluorescence detection for the simultaneous determination of the four most important anthracyclines (doxorubicin, epirubicin, daunorubicin and idarubicin) and their ...
Maudens, Kristof
core
Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy
British Journal of Haematology, EarlyView.
Isacco Ferrarini +19 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Doxorubicin (DOX) is a highly effective anthracycline, whose clinical application for cancer is limited by cardiotoxicity. The mechanisms underlying doxorubicin‐induced toxic cardiomyopathy (DICM) involve electrophysiological remodelling with intracellular Na+ overload because of increased late INa and hyperactivation of
Anna‐Lena Feder +7 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys +14 more
wiley +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
British Journal of Pharmacology, EarlyView.Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source